CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

How Can Artificial Intelligence Improve...

Jorine Putter, Head of Advanced Analytics at...

How Technology Enhances The Effectiveness...

Patrik Florencio, SVP and Chief Compliance & Risk...

Immudex Releases dCode Dextramer Reagants

Jeremy Williams, Life Science Review

The Evolving Role of Technology in Pharma

Aarti Shah, Ph.D., Senior Vice President, Chief...

The Imperative Need for BI and CDS Tech in...

Denise Juliano, Group Vice President of Life...

Maintaining A Patient-Focused Community...

Dale Danilewitz, Executive Vice President & CIO,...

Multiomic Preclinical Models to Define the...

Mitch Sanders, Chief Scientific Officer and EVP of...

Developing Patient-Centric Precision...

Sanjay Konagurthu, Senior Director, PDS Global...

How Can Artificial Intelligence Improve...

Jorine Putter, Head of Advanced Analytics at...

How Technology Enhances The Effectiveness...

Patrik Florencio, SVP and Chief Compliance & Risk...

Immudex Releases dCode Dextramer Reagants

Jeremy Williams, Life Science Review

The Evolving Role of Technology in Pharma

Aarti Shah, Ph.D., Senior Vice President, Chief...

The Imperative Need for BI and CDS Tech in...

Denise Juliano, Group Vice President of Life...

Maintaining A Patient-Focused Community...

Dale Danilewitz, Executive Vice President & CIO,...

Multiomic Preclinical Models to Define the...

Mitch Sanders, Chief Scientific Officer and EVP of...

Developing Patient-Centric Precision...

Sanjay Konagurthu, Senior Director, PDS Global...

Digitizing Pharmaceuticals

By Ashok Upadhyay, IT Director, Otsuka Pharmaceutical Development & Commercialization, Inc. (U.S.)
Tweet

In the world of omnipresent social media and smart user-centric devices, digital technologies continue to redefine newer and better ways for people to interact with one another. Ironically the compliance-led pharma and life sciences industries have not always reacted to adapt and adopt opportunities presented by the creative and inventive union of the digital technologies (social media, mobility, big data, advanced analytics, cloud computing, and IOTs). Amidst the fierce competition in the race to discover, develop, and market novel therapies that unequivocally demonstrate improved patient outcomes, pharma and biotech CIOs must make it a priority for their enterprise IT strategies to focus on digital accelerations as one of the many ways to drive rapid business growth.


The uptake of cloud computing and cloud-based solutions across all pharmaceutical domains has opened up a multitude of possibilities. A few examples include rapid extraction of real-time multi-center clinical study data for scientific and operational analytics, population health management, heath economics and outcomes research, directly engaging with patients through the emergence of social platforms, accelerated use of digital channels for enhanced stakeholder engagement, end-to-end product tracking and real-time monitoring of consumption patterns for enriched inventory management—all of these with unmatched scalability, reliability, and data security at a fraction of the cost compared to traditional non-cloud based solutions.


In late 2015, U.S. FDA accepted the first digital medicine NDA for a potential product that combines an approved medicine for treating certain mental illnesses with an ingestible sensor in a single tablet to digitally record ingestion and, with patient consent, share information with their healthcare professionals and caregivers— which brings significant opportunity to demonstrate the potential of digital medicines to provide an objective measure of medication adherence and physiologic response. This is truly one of the examples of how smart devices in combination with therapeutics may have the potential to impact healthcare.


The uptake of cloud computing and cloud-based solutions across all pharmaceutical domains has opened up a multitude of possibilities


Medication adherence continues to be a huge problem in an era when smart technologies may provide a solution. If I had to bet on the next wave of transformational digital therapeutics, the type of devices with the ability to connect and talk to each other without needing any cloud or server to exchange information among each other (often referred to as “Internet of Things” or IoT) would win my vote.


Both life sciences and healthcare companies have a big opportunity to change the delivery of health and wellness services through the intelligent use of such devices. Imagine a world of possibilities where a number of such sensors and devices interact with each other in a cluster of cohorts generating signals and actions to influence and create human or machine interventions across the healthcare ecosystem. The Big Data strategies are then bound to become the core competitive differentiators for pharma and biotech companies in managing such data explosion to help data scientists ask the right questions. In the process of doing so they will need to revisit the entire IT enterprise—not just by re-evaluating their current platform investment and technical approaches, but more broadly continuing to evolve their policies, organization structures, governance models and most importantly how they engage with internal and external stakeholders, researchers, patients, and customers. They will also need to develop new data strategies that reflect the shift in how data is shared and analyzed, as well as a plan to manage all types of data that affect product sales, pricing, reimbursement and other measures—all while simultaneously focusing more time, energy and investment in digitizing assets to greatly impact the ultimate outcome— disease prevention and improvement of health and wellness around the world.


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Veeva Europe 2023

    Top Vendors

    Current Issue

Read Also

Multiomic Preclinical Models to Define the Mechanism of Action

Mitch Sanders, Chief Scientific Officer and EVP of the ProDevLab, at Alira Health

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Sanjay Konagurthu, Senior Director, PDS Global Science and Technology, Thermo Fisher Scientific

What the New EMA Draft "Guideline on Computerised Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Director, Technology Quality Assurance, Parexel

Pharmaceutical Tablet Coating - Past, Present and Future

Steve Brown, Senior Director EU and APAC Global Manufacturing Science and Technology, Teva Pharmaceuticals [NYSE: TEVA]

Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna

Achieving trial master file quality, timeliness and completeness

Susan K. Maue, Designation : Managing Director PharmaLex

Antibodies: The Building Blocks of Cures

John Armstrong, Head of Research; Head of BD; Global Strategic Programs; Global Straegic Marketing, Galderma

The Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna
Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://bioanalytical-services.lifesciencesreview.com/cxoinsight/digitizing-pharmaceuticals-nwid-189.html